Navigation Links
Mylan Announces Settlement Agreement for Namenda®
Date:7/22/2010

PITTSBURGH, July 22 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda® Tablets, 5 mg and 10 mg, known generically as Memantine Hydrochloride (HCl) Tablets.

Pursuant to the settlement and license agreements, Mylan will have the right to market Memantine HCl in the U.S. on Jan. 11, 2015, or earlier, under certain circumstances. Namenda had U.S. sales of $1.2 billion for the twelve months ending March 31, 2010, according to IMS Health. Additional details of the agreement remain confidential and remain subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Currently, Mylan has 131 ANDAs pending FDA approval representing $92.1 billion in annual brand sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $21.4 billion in annual brand sales, for the 12 months ending Dec. 31, 2009 according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Mylan to Acquire Bioniche Pharma Global Injectable Pharmaceuticals Business
2. RoundTable Healthcare Partners Announces Sale of Bioniche Pharma Holdings Limited to Mylan Inc.
3. Mylan Receives Approval for Nabumetone Tablets
4. Mylan Schedules Second Quarter 2010 Financial Results Conference Call and Live Webcast
5. Mylan Receives Approval for Generic Version of Arimidex® Tablets
6. Mylan Receives Approval for Generic Version of Zocor® Tablets
7. Mylan Receives Approval for Hydroxyzine Hydrochloride Tablets
8. Mylan Receives Approval for Generic Version of Neurontin® Tablets
9. Mylan Receives Approval for Generic Version of Valtrex®
10. Mylan Launches Temazepam Capsules USP, 7.5 mg
11. Mylan Announces Completion of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- Hyland Software expands upon its extensive expertise ... Clinical Leadership Team. Led by nurses and comprised ... healthcare experience, the team will leverage its knowledge ... solutions that will enhance the clinical experience and ... Healthcare organizations use OnBase, Hyland Software,s ...
(Date:5/20/2013)... May 20, 2013  Rhythm announced today the presentation ... higher prevalence of gastroparesis symptoms among diabetic patients in ... is high among patients with both type 1 and ... among those with the more common type 2 disease. ... MD, PhD, Associate Professor of Medicine at Harvard Medical ...
(Date:5/20/2013)... , May 20, 2013 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... offering a greater effect on quality of life ... Given the high level of subjectivity and variability ... interviewed thought leaders state that it is difficult ...
Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... 20, 2013 Mirena IUD lawsuit ... multidistrict litigation recently established in U.S. District Court, Southern ... According to court records, the litigation’s first Status Conference ... to Plaintiff’s leadership positions were discussed. So far, ... Southern District of New York, all of which allege ...
(Date:5/20/2013)... 2013 Salt Lake Community College’s Know Greater ... Select 25 winners for 2013. As part of the ... Greater Heroes is a leadership training program that involves SLCC ... how to eat right, be active, and avoid drugs and ... Greater Heroes program each year, and visit more than 30 ...
(Date:5/20/2013)... judge overseeing pretrial proceedings in the federal consolidation of ... to be included in a plaintiffs’ leadership committee, according ... judge’s request, noting that its lawyers can help ... side effects and how to file a lawsuit. , ... female lawyers to the committee. This followed requests from ...
(Date:5/20/2013)... Amsterdam, NL, 20 May 2013 While Huntington,s ... community anticipates that new disease-modifying therapies in development ... success of HD research depends upon the identification ... and evaluate therapies, and these biomarkers may eventually ... Biomarkers could be especially helpful to monitor changes ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3
... wellbeing and inclusion of former politically motivated prisoners in ... (Monday 14 March). Ageing and Social Exclusion ... the border region of Ireland investigated the well being ... former prisoners (aged 50 and over) as older people ...
... (March 14, 2011) Research has shown that playing a ... children, but playing a used instrument also can pose a ... instruments were found to be heavily contaminated with a variety ... minor to serious infectious and allergic diseases, according to a ...
... (HealthDay News) -- Watching this year,s NCAA March Madness basketball ... on the games, one expert suggests. Though the current ... boards seems to suggest that predicting the outcome of games ... Nowlis, a marketing professor at the Olin Business School at ...
... to resist the targeted drug Herceptin, but a single ... vulnerability to treatment, scientists at The University of Texas ... Nature Medicine . Adding the drug saracatinib to ... at least five different molecular pathways, each of which ...
... , FRIDAY, March 11 (HealthDay News) -- People would prefer ... especially if they know others are watching, says a new ... likely to think badly of them if they do something ... to the research in the journal Psychological Science . ...
... March 11 (HealthDay News) -- A doctor,s empathy can improve ... important part of being a good doctor, according to a ... between July 2006 and June 2009 by 29 doctors at ... doctors, level of empathy for patients, while the quality of ...
Cached Medicine News:Health News:Report into well-being and inclusion of former politically motivated prisoners 2Health News:Report into well-being and inclusion of former politically motivated prisoners 3Health News:Is your child's hobby making him sick? 2Health News:Combination overcomes breast cancer resistance to herceptin 2Health News:Combination overcomes breast cancer resistance to herceptin 3Health News:When Someone Is Watching, You're Less Inclined to Do Bad Things 2
XL STABI Hydrophilic Acrylic Lens....
XL OCTO Hydrophilic Acrylic Lens....
One piece multifocal acrylic intraocular lens....
MemoryLens Prefolded Acrylic Lens....
Medicine Products: